News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 24, 2024

Insights from the TROPION-Lung05 Trial at ASCO 2024

Author(s)Jason Porter, MD

Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.

Episodes in this series

This series features 1 KOL.

EP. 1 Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 2 ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

Jason Porter, MD, an expert on lung cancer

EP. 3 Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 4 Insights from the TROPION-Lung05 Trial at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 5 Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 6 ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Video content above is prompted by the following questions:

Discuss the data that was presented at the ASCO 2024 on intracranial overall response rate in the TROPION-Lung05 trial with Dato-DXd in patients with brain metastasis from NSCLC.
What are your key takeaways from this study and how will this impact the treatment of patients with brain metastasis from NSCLC?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access